Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.

[1]  S. Connolly,et al.  Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. , 2019, Stroke.

[2]  Deepak L. Bhatt,et al.  Stroke Outcomes in the COMPASS Trial , 2019, Circulation.

[3]  S. Connolly,et al.  Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[4]  S. Connolly,et al.  Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source , 2018, The New England journal of medicine.

[5]  Deepak L. Bhatt,et al.  Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial , 2018 .

[6]  Cryptogenic Stroke and Nonstenosing Intracranial Calcified Atherosclerosis. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[7]  S. Kasner,et al.  Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial , 2017, The Lancet Neurology.

[8]  H. Diener.  The cause of stroke matters for secondary prevention , 2017, The Lancet Neurology.

[9]  J. Pogue,et al.  Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial , 2016, European stroke journal.

[10]  S. Connolly,et al.  Embolic strokes of undetermined source: the case for a new clinical construct , 2014, The Lancet Neurology.